IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody, for treatment of head and neck cancer

Bibliography

• GREENLEE RT, HILL-HARMON MB, MURRAY T, THUN M: Cancer statistics, 2001. CA. Cancer J. Chit. (2001) 51:15–36.
   PubMed Web of Science ®Google Scholar
• VOKES EE, WEICHSELBAUM RR, LIPPMAN SM, HONG WK: Medical progress: head and neck cancer. N Engl. Med. (1993) 328:184–194.
   PubMed Web of Science ®Google Scholar
• JACOBS C: The internist in the management of head and neck cancer. Ann. Intern. Med. (1990) 113:771–778.
   PubMed Web of Science ®Google Scholar
• VOKES EE: Head and neck cancer. In: Chemotherapy Source Book. MC Perry (Ed.) Williams & Wilkins, MD, USA (1992):918–931.
   Google Scholar
• TUPCHONG L, SCOTT CB, BLITZER PH eta].: Randomized study of preoperative versus postoperative radiation therapy in advanced head and neck carcinoma: long-term follow-up of RTOG study 73–03. Int. Radiat. Oricol. Biol. Phys. (1991) 20:21–28.
   Google Scholar
• HARARI PM, KINSELLA TJ: Advances in radiation therapy for head and neck cancer. Curr. Opirt. Oricol. (1995) 7:248–254.
   PubMedGoogle Scholar
• FOWLER JF, LINDSTROM MJ: Loss of local control with prolongation in radiotherapy. Int. j Radiat. Oricol. Biol. Phys. (1992) 23:457–467.
   PubMed Web of Science ®Google Scholar
• HUANG S-M, LI J, HARARI PM: Monoclonal antibody blockade of the epidermal growth factor receptor in cancer therapy. In: Cancer Chemotherapy and Biologic Response Modifiers. G Giaccone, R Schilsky, P Sondel (Eds.) Elsevier at Amsterdam, The Netherlands (2001):339–352.
   Google Scholar
• WELLS A: The epidermal growth factor receptor (EGFR) - a new target in cancer therapy. Signal (2001) 1:4–11.
   Google Scholar
• HUANG S-M, HARARI PM: Epidermal growth factor receptor inhibition in cancer therapy: biology, rationale and preliminary clinical results. Invest. New Drugs (1999) 17:259–269.
   PubMed Web of Science ®Google Scholar
• BASELGA J: New technologies in epidermal growth factor receptor-targeted cancer therapy. Signal (2001) 1:12–21.
   Google Scholar
• BASELGA J, MENDELSOHN J: Receptor blockade with monoclonal antibodies as anticancer therapy. Pharmacol Ther. (1994) 64:127–154.
   PubMed Web of Science ®Google Scholar
• MODJTAHEDI H, STYLES JM, DEAN CJ: The human EGF receptor as a target for cancer therapy: six new rat mAbs against the receptor on the breast carcinoma MDA-MB 468. Br. J. Cancer (1993) 67:247–253.
   PubMed Web of Science ®Google Scholar
• PREWETT M, ROCKWELL E ROCKWELL RF et al: The biologic effects of C225, a chimeric monoclonal antibody to the EGFR, on human prostate carcinoma. I Immunother. Emphasis Tumour Immunol (1996) 19:419–427.
   PubMed Web of Science ®Google Scholar
• YANG XD, JIA XC, CORVALAN JR et al: Eradication of established tumours by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy. Cancer Res. (1999) 59:1236–1243.
   PubMed Web of Science ®Google Scholar
• FRY DW: Inhibition of the epidermal growth factor receptor family of tyrosine kinases as an approach to cancer chemotherapy: progression from reversible to irreversible inhibitors. Pharmacol Ther. (1999) 82:207–218.
   PubMed Web of Science ®Google Scholar
• SCHMIDT M, WELS W: Targeted inhibition of tumour cell growth by a bispecific single-chain toxin containing an antibody domain and TGFa. Br. I Cancer (1996) 74:853–862.
   PubMed Web of Science ®Google Scholar
• CHANDLER LA, SOSNOWSKI BA, MCDONALD JR etal.: Targeting tumour cells via EGF receptors: selective toxicity of an HBEGF-toxin fusion protein. Irm Cancer (1998) 78:106–111.
   Google Scholar
• AZEMAR M, SCHMIDT M, ARLT F et al.: Recombinant antibody toxins specific for ErbB2 and EGF receptor inhibit the in vitro growth of human head and neck cancer cells and cause rapid tumour regression in vivo. Int. j Cancer (2000) 86:269–275.
   PubMed Web of Science ®Google Scholar
• RUBIN GRANDIS J, CHAKRABORTY A, MELHEM MF, ZENG Q, TWEARDY DJ: Inhibition of epidermal growth factor receptor gene expression and function decreases proliferation of head and neck squamous carcinoma but not normal mucosal epithelial cells. Oncogene (1997) 15:409–416.
   PubMed Web of Science ®Google Scholar
• ••Decreased cellular proliferation andgrowth in SCC H&N was demonstrated in response to EGFR mRNA blockade using antisense oligonucleotides and tryrosine kinase inhibition, while growth of normal mucosal cells in non-cancer patients were unaffected.
   Google Scholar
• MORONI MC, WILLINGHAM MC, BENGUINOT L: EGF-R antisense RNA blocks expression of the epidermal growth factor receptor and suppresses the transforming phenotype of a human carcinoma cell line. j Biol. Chem. (1992) 267:2714–2722.
   PubMed Web of Science ®Google Scholar
• HEY, ZENG Q, DRENNING SD et al: Inhibition of human squamous cell carcinoma growth in vivo by epidermal growth factor receptor antisense RNA transcribed from the U6 promoter. j Natl. Cancer Inst. (1998) 90:1080–1087.
   PubMed Web of Science ®Google Scholar
• CARPENTER G, COHEN S: Epidermal growth factor. I Biol. Chem. (1990) 265:7709–7712.
   Web of Science ®Google Scholar
• HARARI PM, HUANG S-M: Modulation of molecular targets to enhance radiation. Chu. Cancer Res. (2000) 6:323–325.
   PubMed Web of Science ®Google Scholar
• SCHLESSINGER J: The epidermal growth factor receptor as a multifunctional allosteric protein. Biochemistry (1988) 27:3119–3123.
   PubMed Web of Science ®Google Scholar
• SALOMON DS, BRANDT R, CIARDIELLO F, NORMANNO N: Epidermal growth factor-related peptides and their receptors in human malignancies. Crit. Rev Oncold-lematol. (1995) 19:183–232.
   PubMed Web of Science ®Google Scholar
• CARPENTER G, COHEN S: Epidermal growth factor. Ann. Rev Biochem. (1979) 48:193–216.
   PubMed Web of Science ®Google Scholar
• YARDEN Y, ULLRICH A: Growth factor receptor tyrosine kinases. Ann. Rev Biochem. (1988) 57:443–478.
   PubMed Web of Science ®Google Scholar
• •Describes the structure, function and oncogenic potential of receptor tyrosine kinases, as well as signalling events subsequent to their activation via ligand binding.
   Google Scholar
• YARDEN Y, SLIWKOWSKI MX: Untangling the ErbB signalling network. Nat. Rev Ma Cell. Biol. (2001) 2:127–136.
   PubMed Web of Science ®Google Scholar
• CARPENTER G, COHEN S: 125I-labelled human epidermal growth factor: binding, internalization and degradation in human fibroblasts. J Cell. Biol. (1976) 71:159–171.
   PubMed Web of Science ®Google Scholar
• RODECK U, JOST M, KARI C etal.: EGF-R dependent regulation of keratinocyte survival. j Cell. Sci. (1997) 110:113–121.
   Google Scholar
• GIBSON S, TU S, OYER R, ANDERSON SM, JOHNSON GL: Epidermal growth factor protects epithelial cells against Fas-induced apoptosis. j Biol. Chem. (1999) 274:17612–17618.
   PubMed Web of Science ®Google Scholar
• PETIT AMV, RAK J, HUNG M-C et al: Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases downregulate vascular endothelial growth factor production by tumour cells in vitro and in vivo. Am. Pathol (1997) 151:1523–1530.
   PubMed Web of Science ®Google Scholar
• PERROTTE P, MATSUMOTO T, INOUE K et al.: Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. Chu. Cancer Res. (1999) 5:257–264.
   PubMed Web of Science ®Google Scholar
• •In vitro treatment with IMC-C225 significantly lowered the production of VEGF, IL-8 and bFGF, indicating that antitumour effects associated with EGRF blockade are partially mediated by the inhibition of angiogenesis.
   Google Scholar
• KONDAPAKA SB, FRIDMAN R, REDDY KB. Epidermal growth factor and amphiregulin upregulate matrix metalloproteinase-9 (IVIMP-9) in human breast cancer cells. Int. j Cancer (1997) 70:722–726.
   Google Scholar
• PRICE JT, WILSON HM, HAITES NE: Epidermal growth factor (EGF) increases the in vitro invasion, motility and adhesion interactions of the primary renal carcinoma cell line, A704. Eur. j Cancer (1996) 32A:1977–1982.
   PubMed Web of Science ®Google Scholar
• SHIBATA T, KAWANO T, NAGAYASU H etal.: Enhancing effects of epidermal growth factor on human squamous cell carcinoma motility and matrix degradation but not growth. Tumour Biol. (1996) 17:168–175.
   Google Scholar
• MATSUMOTO T, PERROTTE P, BAR-ELI M et al: Blockade of EGF-R signalling with antiEGF-R monoclonal antibody (Mab) C225 inhibits matrix metalloproteinases-9 (MIVIP-9) expression and invasion of human transitional cell carcinoma (TCC) in vitro and in vivo. Proc. Am. Assoc. Cancer Res. (1998) 39:565 (Abstract).
   Google Scholar
• XIE H, TURNER T, WANG M-H, SINGH RK, SIEGAL GP, WELLS A: In vitro invasiveness of DU-145 human prostate carcinoma cells is modulated by EGF receptor-mediated signals. Chu. Exp. Metastasis (1995) 13:407–419.
   PubMed Web of Science ®Google Scholar
• CARPENTER G: Receptors for epidermal growth factor and other polypeptide mitogens. Ann. Rev Biochem. (1987) 56:881–914.
   PubMed Web of Science ®Google Scholar
• GULLICK WJ: Prevalence of aberrant expression of the epidermal growth factor receptor in human cancers. Br Med. Bull. (1991) 47:87–98.
   PubMed Web of Science ®Google Scholar
• SHIN DM, RO JY, HONG WK, HITTELMAN WN: Dysregulation of epidermal growth factor receptor expression in premalignant lesions during head and neck tumourigenesis. Cancer Res. (1994) 54:3153–3159.
   PubMed Web of Science ®Google Scholar
• GRANDIS JR, MELHEM MF, BARNES EL, TWEARDY DJ: Quantitative immunohistochemical analysis of transforming growth factor-a and epidermal growth factor receptor in patients with squamous cell carcinoma of the head and neck. Cancer (1996) 78:1284–1292.
   PubMed Web of Science ®Google Scholar
• ••Determined by computerised imageanalysis of IHC staining, EGFR and TGF-a expression is increased in the tissues of patients with SCC H&N cancers over controls. Increased EGFR staining was associated with a closer proximity to the tumour or higher degrees of dysplasia.
   Google Scholar
• STANTON P, RICHARDS S, REEVES Jet al.: Epidermal growth factor receptor expression by human squamous cell carcinomas of the head and neck, cell lines and xenografts. Br .j Cancer (1994) 70:427–433.
   Google Scholar
• KAWAMOTO T, TAKAHASHI K, NISHI M, KIMURA T, MATSUMURA T, TANIGUCHI S: Quantitative assay of epidermal growth factor receptor in human squamous cell carcinomas of the oral region by an avidin-biotin method. fpri. j Cancer Res. (1991) 82:403–410.
   PubMed Web of Science ®Google Scholar
• VOLM M, RITTGEN W, DRINGS P: Prognostic value of ERBB-1, VEGF, cyclin A, FOS, JUN and MYC in patients with squamous cell lung carcinomas. Br. Cancer (1998) 77:663–669.
   Google Scholar
• BARTLETT JMS, LANGDON SP, SIMPSON BJB et al: The prognostic value of epidermal growth factor receptor mRNA expression in primary ovarian cancer. Br Cancer (1996) 73:301–306.
   Google Scholar
• PAVELIC K, BANJAC Z, PAVELIC J, SPAVENTI S: Evidence for a role of EGF receptor in the progression of human lung carcinoma. Anti-Cancer Res. (1993) 13:1133–1138.
   PubMed Web of Science ®Google Scholar
• NEAL DE, SHARPLES L, SMITH K etal.: The epidermal growth factor receptor and the prognosis of bladder cancer. Cancer (1990) 65:1619–1625.
   Google Scholar
• NIIKURA H, SASANO H, SATO S, YAJIMA A: Expression of epidermal growth factor-related proteins and epidermal growth factor receptor in common epithelial ovarian tumours. bit. I Cyrrecol. Pathol. (1997) 16:60–68.
   PubMed Web of Science ®Google Scholar
• GRANDIS JR, MELHEM MF, GOODING WE et al: Levels of TGF-a and EGFR protein in head and neck squamous cell carcinoma and patient survival. ..J. Natl. Cancer Inst. (1998) 90:824–832.
   PubMed Web of Science ®Google Scholar
• ••This paper identified the significantrelationships between increased tumour levels of EGFR and TGF-a in SCC 118rN cancers and decreased disease-free and cause-specific survival.
   Google Scholar
• MAURIZI M, ALMADORI G, FERRANDINA G et al: Prognostic significance of epidermal growth factor receptor in laryngeal squamous cell carcinoma. Br .j Cancer (1996) 74:1253–1257.
   PubMed Web of Science ®Google Scholar
• TODD R, DONOFF BR, GERTZ R et al: TGF-a and EGF-receptor mRNAs in human oral cancers. Carcirrogerresis (1989) 10:1553–1556.
   PubMed Web of Science ®Google Scholar
• SANTINI J, FORMENTO J-L, FRANCOUAL M et al.: Characterization, quantification and potential clinical value of the epidermal growth factor receptor in head and neck squamous cell carcinomas. Head Neck (1991) 13:132–139.
   PubMed Web of Science ®Google Scholar
• KE LD, ADLER -STORTHZ K, CLAYMAN GL, YUNG AWK, CHEN Z: Differential expression of epidermal growth factor receptor in human head and neck cancers. Head Neck (1998) 20:320–327.
   PubMed Web of Science ®Google Scholar
• MENDELSOHN J: Epidermal growth factor receptor inhibition by a monoclonal antibody as anticancer therapy. OM. Cancer Res. (1997) 3:2703–2707.
   Web of Science ®Google Scholar
• ••Mendelsohn reviews his research of mAbC225's antitumour mechanisms related to EGFR blockade. Supported hypotheses include inhibition of cell cycle progression and a subsequent decrease incellular proliferation, as well as downregulation of EGF receptors. It is postulated that an enhanced antitumour response, (i.e., cellular death) associated with combined mAb C225 and chemotherapy is related to activation of two separate checkpoints in the cell cycle.
   Google Scholar
• SHITARA K, KUWANA Y, NAKAMURA K et al.: A mouse/human chimeric antfiganglioside GD3) antibody with enhanced antitumour activities. Cancer Immurrol. Immunother. (1993) 36:373–380.
   PubMed Web of Science ®Google Scholar
• LOBUGLIO AF, WHEELER RH, TRANG J et al: Mouse/human chimeric monoclonal antibody in man: kinetics and immune response. Proc. Natl. Acad. Li. USA (1989) 86:4220–4224.
   PubMed Web of Science ®Google Scholar
• GOLDSTEIN NI, PREWETT M, ZUKLYS K, ROCKWELL P, MENDELSOHN J: Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumour xenograft model. Clin. Cancer Res. (1995) 1:1311–1318.
   PubMed Web of Science ®Google Scholar
• GILL GN, KAWAMOTO T, COCHET C et al.: Monoclonal anti-epidermal growth factor receptor antibodies which are inhibitors of epidermal growth factor binding and antagonists of epidermal growth factor-stimulated tyrosine protein kinase activity. I Biol. Chem. (1984) 259:7755–7760.
   Web of Science ®Google Scholar
• KAWAMOTO T, MENDELSOHN J, LE A, SATO GH, LAZAR CS, GILL GN: Relation of epidermal growth factor receptor concentration to growth of human epidermoid carcinoma A431 cells. j Biol. Chem. (1984) 259:7761–7766.
   PubMed Web of Science ®Google Scholar
• KAWAMOTO T, SATO JD, LEA, POLIKOFF J, SATO GH, MENDELSOHN J: Growth stimulation of A431 cells by epidermal growth factor: identification of high-affinity receptors for epidermal growth factor by an antireceptor monoclonal antibody. Proc. Natl Acad. Sci. USA (1983) 80:1337–1341.
   PubMed Web of Science ®Google Scholar
• SATO JD, KAWAMOTO T, LEAD, MENDELSOHN J, POLIKOFF J, SATO GH: Biological effects in vitro of monoclonal antibodies to human epidermal growth factor receptors. Ma Biol. Med. (1983) 1:511–529.
   Google Scholar
• SUNADA H, MAGUN BE, MENDELSOHN J, MACLEOD CL: Monoclonal antibody against epidermal growth factor receptor is internalized without stimulating receptor phosphorylation. Proc. Natl Acad Sci. USA (1986) 83:3825–3829.
   PubMed Web of Science ®Google Scholar
• BASELGA J, PFISTER D, COOPER MR et al.: Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. j Clin. amyl. (2000) 18:904–914.
   Web of Science ®Google Scholar
• ••Pharmacokinetic study using escalatingdoses of IMC-C225 demonstrates saturable clearance with doses ranging between 200 and 400 mg/m2 supporting saturation of EGFR sites. Combined treatment with cisplatin did not alter C225 clearance and was well-tolerated.
   Google Scholar
• SHIN DM, DONATO NJ, PEREZ- SOLER R etal.: Epidermal growth factor receptor-targeted therapy with C225 and cisplatin in patients with head and neck cancer. Chu. Cancer Res. (2001) 7:1204–1213.
   Google Scholar
• HUANG S-M, BOCK JM, HARARI PM: Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis and radiosensitivity in squamous cell sarcomas of the head and neck. Cancer Res. (1999) 59:1935–1940.
   PubMed Web of Science ®Google Scholar
• WU X, RUBIN M, FAN Z et al: Involvement of p261(11P1 in G1 arrest mediated by an anti-epidermal growth factor receptor monoclonal antibody. Oncogene (1996) 12:1397–1403.
   PubMed Web of Science ®Google Scholar
• PENG D, FAN Z, LU Y, DEBLASIO T, SCHER H, MENDELSOHN J: Anti-epidermal growth factor receptor monoclonal antibody C225 upregulates p27 KIP1 and induces G1 arrest in prostatic cancer cell line DU145. Cancer Res. (1996) 56:3666–3669.
   PubMed Web of Science ®Google Scholar
• WU X, FAN Z, MASUI H, ROSEN N, MENDELSOHN J: Apoptosis induced by an anti-epidermal growth factor receptor monoclonal antibody in a human colorectal carcinoma cell line and its delay by insulin. Chu. Invest. (1995) 95:1897–1905.
   PubMed Web of Science ®Google Scholar
• MANDAL M, ADAM L, MENDELSOHN J, KUMAR R: Nuclear targeting of Box during apoptosis in human colorectal cancer cells. Oncogene (1998) 17:999–1007.
   PubMed Web of Science ®Google Scholar
• LIU B, FANG M, SCHMIDT M, LU Y, MENDELSOHN J, FAN Z: Induction of apoptosis and activation of the caspase cascade by antiEGF receptor monoclonal antibodies in DiFi human colon cancer do not involve the c-jun N-terminal kinase activity. Br. J. Cancer (2000) 82:1991–1999.
   PubMed Web of Science ®Google Scholar
• HUANG S-M, HARARI PM: Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics and tumour angiogenesis. Chu. Cancer Res. (2000) 6:2166–2174.
   PubMed Web of Science ®Google Scholar
• BRUNS CJ, HARBISON MT, DAVIS DW et al.: Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by anti-angiogenic mechanisms. Chu. Cancer Res. (2000) 6:1936–1948.
   PubMed Web of Science ®Google Scholar
• HARARI PM, HUANG S-M: Head and neck neck cancer as a clinical model for molecular targeting of therapy: combining EGFR blockade with radiation. Int. j Rad. °ma. Biol. Phys. (2001) 49:427–433.
   PubMed Web of Science ®Google Scholar
• ZHU A, SHAEFFER J, LESLIE S, KOLM P, EL-MAHDI AM: Epidermal growth factor receptor: an independent predictor of survival in astrocytic tumours given definitive irradiation. Int. j Radiat. °ma. Biol. Phys. (1996) 34:809–815.
   PubMed Web of Science ®Google Scholar
• SHERIDAN MT, O& DWYER T, SEYMOUR CB, MOTHERSILL CE: Potential indicators of radiosensitivity in squamous cell carcinoma of the head and neck. Radiat. Oricol Investig. (1997) 5:180–186.
   PubMedGoogle Scholar
• ILIAKIS G: Cell cycle regulation in irradiated and nonirradiated cells. Semi]. °ma. (1997) 24:602–615.
   PubMed Web of Science ®Google Scholar
• PREWETT M, ROCKWELL P, ROSE C, GOLDSTEIN NI: Antitumour and cell cycle responses in KB cells treated with a chimeric antiEGFR monoclonal antibody in combination with cisplatin. Int. j Oricol (1996) 9:217–224.
   PubMed Web of Science ®Google Scholar
• FAN Z, BASELGA J, MASUI H, MENDELSOHN J: Antitumour effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts. Cancer Res. (1993) 53:4637–4642.
   PubMed Web of Science ®Google Scholar
• ••Combined treatment with mAb C225 andcisplatin in cell cultures of A431 tumour xenografts resulted in significant inhibition of tumour growth.
   Google Scholar
• WEN X, LI C, WU Q-P et al: Potentiation of antitumour activity of PG-TXL with antiEGFR monoclonal antibody C225 in MDA-MB-468 human breast cancer xenograft. Proc. Am. Assoc. Cancer Res. (2000) 41:323. (Abstract 2052).
   Google Scholar
• PREWETT M, ROCKWELL P, ROSE C, ZUKLYS K, GOLDSTEIN NI: Altered cell cycle distribution and cyclin-CDK protein expression in A431 epidermoid carcinoma cells treated with doxorubicin and a chimeric monoclonal antibody to the epidermal growth factor receptor. Ma Cell. Duff (1996) 4:167–186.
   Web of Science ®Google Scholar
• BASELGA J, NORTON L, MASUI H et al.: Antitumour effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies. Natl. Cancer Inst. (1993) 85:1327–1333.
   Google Scholar
• GOLDSTEIN NI, PREWETT M, ROCKWELL P, ZALICSKY S, WORXING P: Treatment of human tumour xenografts with a chimeric monoclonal antibody to the epidermal growth factor receptor in combination with DoxilTM, a novel liposomal form of doxorubicin. Monoclonal Antibodies & Cancer Therapy New York, USA October 16–18, 1995 (Abstract).
   Google Scholar
• CIARDIELLO F, BIANCO R, DAMIANO V et al: Antitumour activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225. Chu. Cancer Res. (1999) 5:909–916.
   PubMed Web of Science ®Google Scholar
• OVERHOLSER JP, PREWETT MC, HOOPER AT, WAKSAL HW, HICKLIN DJ: Epidermal growth factor receptor blockade by antibody IMC-C225 inhibits growth of a human pancreatic carcinoma xenograft in nude mice. Cancer (2000) 89:74–82.
   PubMed Web of Science ®Google Scholar
• RABEN D, BUCHSBAUM DJ, GILLESPIE Y, RANDALL S, SALEH M, WAKSAL H: Treatment of human intracranial gliomas with chimeric monoclonal antibody against the epidermal growth factor receptor increases survival of nude mice when treated concurrently with irradiation. Proc. Am. Assoc. Cancer Res. (1999) 40:184. (Abstract 1224).
   Google Scholar
• SALEH MN, RAISCH KP, STACKHOUSE MA etal.: Combined modality therapy of A431 human epidermoid cancer using antiEGFR antibody C225 and radiation. Cancer &other. Radiopharm. (1999) 14:451–463.
   Google Scholar
• TRUMMELL HQ, RAISCH KP AHMED A, BONNER JA: The biological effects of anti-epidermal growth factor receptor and ionizing radiation in human head and neck tumour cell lines. Proc. Am. Assoc. Cancer Res. (1999) 40:144. (Abstract 958).
   Google Scholar
• MILAS L, MASON K, HUNTER N etal.: In vivo enhancement of tumour radioresponse by C225 anti-epidermal growth factor receptor antibody. Chu. Cancer Res. (2000) 6:701–708.
   Google Scholar
• •Pretreatment with mAb C225 in mice with A431 tumour xenografts significantly improved the response to local radiotherapy by a factor of 1.59 with single doses and 3.62 with multiple doses.
   Google Scholar
• PEREZ-SOLER R, SHIN DM, DONATO N et al.: Tumour studies in patients with head & neck cancer treated with humanized anti-epidermal growth factor (EGFR) monoclonal antibody C225 in combination with cisplatin. Proc. ASCO (1998) 17:1514 (Abstract).
   Google Scholar
• BONNER JA, EZEKIEL MP, ROBERT F, MEREDITH RF, SPENCER SA, WAKSAL HW: Continued response following treatment with IMC-C225, an EGFr MoAb, combined with RT in advanced head and neck malignancies. Proc. ASCO (2000) 19:5F. (Abstract).
   Google Scholar
• ••This Phase I study provided the impetusfor further clinical trials by demonstrating an excellent (87% complete response) and durable response associated with combined mfith C225 and radiation in patients with locally advanced H&N cancers.
   Google Scholar
• SALTZ L, RUBIN M, HOCHSTER H et al.: Cetuximab (IMC-C225) plus irinotecan (CPT-I1) is active in CPT-11-refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR). Am. Soc. CM]. arca (2001) (Abstract 7).
   Google Scholar
• ABBRUZZESE JL, ROSENBERG A, XIONG Q et al. Phase II study of anti-epidermal growth factor receptor (EGFR) antibody cetuximab (IMC-C225) in combination with gemcitabine in patients with advanced pancreatic cancer. Am. Soc. CM]. Oricol. (2001) (Abstract 518).
   Google Scholar
• HONG WK, ARQUETTE M, NABELL L et al. Efficacy and safety of the anti-epidermal growth factor antibody (EGFR) IMC-C225, in combination with cisplatin in patients with recurrent squamous cell carcinoma of the head and neck (SCCHN) refractory to cisplatin containing chemotherapy. Am. Soc. ChP. °ma. (2001) (Abstract 895).
   Google Scholar
• PREWERT M, HOOPER A, BASSI R et at: Growth inhibition of human colorectal carcinoma xenografts by anti-EGF receptor monoclonal antibody IMC-C225 in combination with 5-fluorouracil or irinotecan. Proc. Am. Assoc. Cancer Res. (2001) (Abstract 42a).
   Google Scholar
• COHEN RB, FALCEY JW, PAULTER VJ, FETZER KM, WAKSAL HW: Safety profile of the monoclonal antibody (MoAb) IMC-C225, an anti-epidermal growth factor receptor (EGFr) used in the treatment of EGFr-positive tumours. Proc. ASCO (2000) 19:1862. (Abstract).
   Google Scholar
• KHAZAELI MB, LOBUGLIO AF, FALCEY JW, PAULTER VJ, FETZER KM, WAKSAL HW: Low immunogenicity of a chimeric monoclonal antibody (MoAb), IMC-C225, used to treat epidermal growth factor receptor-positive tumours. Proc. ASCO (2000) 19:808 (Abstract).
   Google Scholar
• BONNER JA, RAISCH KP, TRUMMELL HQ et al.: Enhanced apoptosis with combination C225/radiation treatment serves as the impetus for clinical investigation in head and neck cancers. CM]. °ma. (2000) 18\(Suppl. 21):475–535.
   Google Scholar
• HUANG SM, BOCK JM, HARARI PM: Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res. (1999) 59(8):1935–1940.
   PubMed Web of Science ®Google Scholar